Skip to content

Are you willing to join us on our journey to save lives by enabling precision medicine?

The discovery and development of biomarkers for precision medicine using single-cell data and AI is unlocking novel disease insights for the global medical community. New avenues for diagnostics and therapeutics for complex diseases are being discovered so that we can unify and save lives.

Study Design

Defining hypothesis
Wet/Dry lab setup and experimental design
Data analysis workflow

Data Acquisition

Identification of suitable single-cell method(s)
Method optimization
Sample preparation and processing

Biomedical insights

Data processing, analysis and interpretation using our AI-based technology

Identification of biomarkers and cell-identity signatures

Diagnostic development

Data processing, analysis and interpretation using our AI-based technology

Identification of biomarkers and  cell-identity signatures

Accelerating pioneering science through strong partnerships

Improved outcomes for patients via:

Our industry partners

Pharmaceutical companies

We are your partner of choice to enable the vision of precision medicine. We discover ultra-sensitive biomarkers to inform various stages of therapy development:

  • screening and stratification of patients for clinical trials (CDx)
  • prediction of therapy response
  • toxicity, efficacy and QC in cell therapy development
  • monitoring of patients post-treatment

ScaiVision identifies a genomic signature that accurately predicts CAR-T cell therapy efficacy in B-cell lymphoma patients

ScaiVision is Scailyte’s in-house platform for analyzing single-cell data, including both scRNA/TCR/BCR-seq and high-parameter proteomics obtained by cytometry techniques such as mass cytometry (CyTOF).

ScaiVision identifies a genomic signature that accurately predicts CAR-T cell therapy efficacy in B-cell lymphoma patients

This example of biomarker discovery for cell therapy efficiency uses a public single-cell RNA sequencing (scRNA-Seq) dataset published by Deng, et al. (2020) in Nature Medicine. scRNA-Seq data of 23 large B cell lymphoma (LBCL) patients treated with CAR-T cell therapy and 3-month follow-up data available were analyzed. AI-driven ScaiVision integrated scRNA-Seq with the follow-up data and discovered a transcriptomic signature predicting complete response (CR, n = 9) vs. partial response or progressive disease (PR/PD, n = 14). A predictive accuracy of 87.5% was achieved on held-out validation samples.

Scailyte calls cell therapy and other pharmaceutical companies which embrace the precision medicine approach. Do you have a drug candidate in preclinical or clinical development? Reach out to us and let’s discuss your specific interests and needs.

Diagnostic companies

Scailyte develops biomarker signatures and assay prototypes for complex diseases. We license our discoveries or engage in co-development projects with diagnostic companies willing to build products and services.

We identify and validate biomarkers and prototype assays for:

  • Screening and diagnosis
  • Prognosis
  • Prediction of therapy response

ScaiVision accurately diagnoses Cutaneous T-Cell Lymphoma

Cutaneous T-cell lymphoma (CTCL) is a rare skin cancer that is often misdiagnosed with atopic dermatitis (AD), a highly prevalent skin condition with similar clinical presentation. Currently used markers and assays have low sensitivity and are inconclusive to diagnose CTCL in early stages, leading to disease progression and up to 5-year delay in diagnosis. Advanced-stage diagnosis requires highly aggressive and costly chemotherapy treatment causing severe side effects. 

ScaiVision accurately diagnoses Cutaneous T-Cell Lymphoma

To address the differential CTCL diagnosis need, we identified CTCL-specific biomarkers using our proprietary single-cell data analysis platform ScaiVision. We have developed an IVD assay prototype using these biomarkers for simple, minimally invasive and cost-effective testing of suspected CTCL patients. The assay enables timely intervention, improves patient Quality of Life (QoL), dramatically reduces treatment costs associated with late-stage/misdiagnosis/comorbidities and, ultimately, saves lives.

Scailyte’s CTCL IVD assay will be the first clinically validated blood-based diagnostic test for CTCL with superior accuracy as compared to the current standard of care diagnostics. The assay will be used to screen recurrent AD patients suspected of CTCL. This approach offers rapid triage of recurrent AD patients at dermatology clinics. The assay will shorten diagnosis up to five years, reducing hospital costs associated with repeated visits and less accurate tests by allowing early treatment and improved patient outcome.



Are you interested in in-licensing a biomarker signature or a diagnostic assay prototype? Would you like to develop an assay for your indication of interest? Let’s discuss our ongoing projects and your specific needs.

Making groundbreaking discoveries requires strong collaborations and joint ventures